Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Inhaled Insulin (AERx iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes.

Trial Profile

Effect of Inhaled Insulin (AERx iDMS) Plus Pioglitazone Versus Pioglitazone Alone on HbA1c in Subjects With Type 2 Diabetes.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2018

At a glance

  • Drugs Insulin (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 13 Oct 2009 Actual initiation date changed from Dec 2006 to Nov 2006 as reported by ClinicalTrials.gov.
    • 31 Jan 2008 Status change from in progress to discontinued, as reported by clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top